<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The aim of this study was to investigate therapeutic outcomes and assess factors associated with therapeutic outcomes in hematologic patients with <z:e sem="disease" ids="C0276653" disease_type="Disease or Syndrome" abbrv="">invasive pulmonary aspergillosis</z:e> (<z:chebi fb="23" ids="17824,30802">IPA</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We analyzed <z:hpo ids='HP_0000001'>all</z:hpo> consecutive cases of <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> in adults with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> from January 2008 to January 2009 at a Catholic Hematopoietic Stem Cell Transplantation (HSCT) Center in Seoul, Korea </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: A total of 54 patients were identified </plain></SENT>
<SENT sid="3" pm="."><plain>Underlying diseases were <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (n=25), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n=10), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n=7), <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (n=3), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (n=3), severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (n=2) and other <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> (n=4) </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty six patients (48.2%) were assessed as having a favorable response, of which 16 patients (29.6%) showed complete response </plain></SENT>
<SENT sid="5" pm="."><plain>Overall 12-week mortality and <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> attributable mortality were 38.9% (n=21) and 33.3% (n=18), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In multivariate analysis, uncontrolled underlying disease (odds ratio [OR], 7.31; 95% confidence interval [CI], 1.49~35.94; p=0.014) was associated with an unfavorable response, and for 12-week mortality, uncontrolled underlying disease (OR, 11.79; 95% CI, 1.49~93.46; p=0.020) and <z:hpo ids='HP_0003073'>hypoalbuminemia</z:hpo> (OR, 9.89; 95% CI, 1.42~68.99; p=0.021) were significantly poor prognostic factors </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> still remains as a poor therapeutic outcome, especially in patients with refractory <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> </plain></SENT>
</text></document>